Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma
Estimate 2-year Mantle Cell Lymphoma PFS2
About
Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma
References
D. Villa, A. Jiang, N. Crosbie, S. Rule, R. McCulloch et al,
Impact of time to second line Bruton tyrosine kinase therapy in patients with first relapse of mantle cell lymphoma:
TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA
Hematological Oncology: 17 June 2021
The Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma calculator is created by QxMD.
By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.